Karyopharm Therapeutics, Inc. (KPTI)
0.605
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 16:00
0.5959
-0.01
(-1.50%)
After-Hours: 20:00
Karyopharm Therapeutics Cash from Operations (Quarterly) : -24.93M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -24.93M |
| March 31, 2026 | -22.73M |
| December 31, 2025 | -11.83M |
| September 30, 2025 | -5.86M |
| June 30, 2025 | -18.70M |
| March 31, 2025 | -38.98M |
| December 31, 2024 | -25.81M |
| September 30, 2024 | -19.45M |
| June 30, 2024 | -38.50M |
| March 31, 2024 | -43.72M |
| December 31, 2023 | -18.58M |
| September 30, 2023 | -29.53M |
| June 30, 2023 | -25.70M |
| March 31, 2023 | -18.91M |
| December 31, 2022 | -26.84M |
| September 30, 2022 | -28.37M |
| June 30, 2022 | -35.14M |
| March 31, 2022 | -59.20M |
| December 31, 2021 | 25.48M |
| September 30, 2021 | -23.96M |
| June 30, 2021 | -55.75M |
| March 31, 2021 | -52.89M |
| December 31, 2020 | -30.63M |
| September 30, 2020 | -44.31M |
| June 30, 2020 | -40.28M |
| Date | Value |
|---|---|
| March 31, 2020 | -45.01M |
| December 31, 2019 | -39.49M |
| September 30, 2019 | -36.51M |
| June 30, 2019 | -48.20M |
| March 31, 2019 | -66.62M |
| December 31, 2018 | -48.17M |
| September 30, 2018 | -38.66M |
| June 30, 2018 | -37.63M |
| March 31, 2018 | -34.65M |
| December 31, 2017 | -5.538M |
| September 30, 2017 | -21.75M |
| June 30, 2017 | -21.72M |
| March 31, 2017 | -24.71M |
| December 31, 2016 | -20.00M |
| September 30, 2016 | -20.33M |
| June 30, 2016 | -20.89M |
| March 31, 2016 | -23.16M |
| December 31, 2015 | -20.38M |
| September 30, 2015 | -25.33M |
| June 30, 2015 | -28.10M |
| March 31, 2015 | -20.22M |
| December 31, 2014 | -12.77M |
| September 30, 2014 | -16.23M |
| June 30, 2014 | -11.88M |
| March 31, 2014 | -10.57M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Madrigal Pharmaceuticals, Inc. | 23.33M |
| Relay Therapeutics, Inc. | -54.11M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -10.04M |
| Cash from Financing (Quarterly) | -0.898M |
| Free Cash Flow | -65.35M |
| Free Cash Flow Per Share (Quarterly) | -0.8615 |
| Free Cash Flow to Equity (Quarterly) | -50.25M |
| Free Cash Flow to Firm (Quarterly) | -11.79M |
| Free Cash Flow Yield | -538.5% |